Details

Autor(en) / Beteiligte

• Perry, James R
• Laperriere, Normand
• O’Callaghan, Christopher J
• Brandes, Alba A
• Menten, Johan
• Phillips, Claire
• Fay, Michael
• Nishikawa, Ryo
• Cairncross, J. Gregory
• Roa, Wilson
• Osoba, David
• Rossiter, John P
• Sahgal, Arjun
• Hirte, Hal
• Laigle-Donadey, Florence
• Franceschi, Enrico
• Chinot, Olivier
• Golfinopoulos, Vassilis
• Fariselli, Laura
• Wick, Antje
• Feuvret, Loic
• Back, Michael
• Tills, Michael
• Winch, Chad
• Baumert, Brigitta G
• Wick, Wolfgang
• Ding, Keyue
• Mason, Warren P

Titel

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

Ist Teil von

• The New England journal of medicine, 2017-03, Vol.376 (11), p.1027-1037

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2017

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Older patients with glioblastoma appear to benefit more from treatment combining a shorter course (3 weeks rather than 6 weeks) of radiotherapy together with temozolomide than from radiotherapy alone. Glioblastoma is a fatal illness that is associated with a median survival of less than 2 years. Population studies of glioblastoma have shown that survival declines with increasing age, 1 , 2 and the incidence of glioblastoma is increasing, especially among the elderly. 3 Older patients have been underrepresented in most randomized trials, in which the average age of participants is approximately 55 years, as compared with the population-based median for patients with glioblastoma of 65 years of age. 2 In 2005, a phase 3 trial of radiotherapy alone (60 Gy over a period of 6 weeks) versus radiotherapy plus temozolomide showed longer survival . . .